A new study was conducted to better understand the landscape of coverage of non-pharmacologic treatments for chronic pain among public and private insurers in the United States. Here’s what it found.
Heyward
A new study was recently conducted to better understand the landscape of coverage of non-pharmacologic treatments for chronic pain.
In the cross-sectional study of 45 Medicaid, commercial, and Medicare Advantage plans, most plans covered at least physical and occupational therapy and chiropractic care for chronic non-cancer pain, but there was little evidence of coverage of acupuncture and psychological interventions.
“We looked at coverage of five commonly prescribed non-pharmacologic treatments for chronic pain, including physical therapy, occupational therapy, chiropractic care, acupuncture, and therapeutic massage, as well as some additional therapies for Medicaid plans only” says study author Jamie Heyward, MPH, research data analyst at the Johns Hopkins Center for Drug Safety and Effectiveness. “We also interviewed 43 executives at those plans so we could understand their plans’ policy changes in response to the opioid epidemic, focusing on coverage of non-pharmacologic therapies.”
The study, published October 1, 2018 in the Journal of the American Medical Association (JAMA) Network Open, was conducted to better understand the landscape of coverage of non-pharmacologic treatments for chronic pain.
“Insurance coverage is an important factor in access to healthcare,” says Heyward. “There are recent guidelines from the CDC and HHS that recommend prescribing non-opioid and non-pharmacologic treatments rather than opioids for chronic pain. No studies have looked at whether insurance coverage policies help or hurt patient access to such treatments. We found that there is spotty coverage of several treatments that have evidence of effectiveness for treating pain, like acupuncture and psychological therapy.”
Most health plans the researchers examined cover therapies like physical and occupational therapy and chiropractic care, according to Heyward. “Even the commonly covered therapies are restricted by policies like visit limits, prior authorization requirements, and referral requirements, which may limit patient access,” he says.
The findings highlight the need for better coverage of alternatives to opioid painkillers for treating chronic pain. “Prescription opioids continue to play a large role in the high rates of addiction, overdose and death in the United States,” Heyward says.
“It is important that healthcare executives take steps to ensure their plans’ policies provide access to the full range of treatment options for patients with chronic pain,” adds Heyward. “This is especially important given the CDC’s opioid prescribing guidelines for doctors, as well other efforts to lower opioid prescribing levels. There is also growing evidence of the effectiveness of non-pharmacologic therapies for chronic pain.”
Other Unique Findings
Study researcher interviews revealed that most plans are making policy changes in response to the opioid epidemic. “However, these policies often focus narrowly on reducing opioid prescribing, rather than improving overall pain care through better coverage of alternative treatments,” Heyward says. “Also, coverage policies for pharmacologic and non-pharmacologic therapies for pain are not coordinated with each other.”
Based on the study, there are five things Heyward wants healthcare execs to know about insurer policies/non-opioid alternatives for pain:
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More